Abstract
TA Lavelle, TM Uyeki, LA Prosser. J Pediatr. 2012;160(1):67–73.e6 To evaluate the cost-effectiveness of oseltamivir treatment for seasonal influenza in children and consider the impact of oseltamivir resistance on these findings. Unvaccinated children, stratified according to age groups (12–23 months, 2 years, 3–4 years, 5–11 years, and 12–17 years) visiting a physician’s office with age-appropriate symptoms of uncomplicated influenza-like illness. The investigators developed a model to evaluate 1-year clinical and economic outcomes associated with 3 …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
